Gilead Reports 17 Percent Earnings Drop Due To Slow Hep C Drug Sales
Gilead Sciences' steep discounts and rebates on Harvoni are hitting the drugmaker's bottom line. And in other pharmaceutical news, The Wall Street Journal reports on upheaval at Valeant.